ID 7.6.49200 Ariceum Therapeutics - Targeted radiopharmaceuticals for difficult to treat cancers

Clinical stage biotech developing peptide radioligand therapies with a theranostic approach.

Ariceum Therapeutics develops peptide radioligand therapies designed to target tumours precisely while sparing healthy tissue. The company advances a theranostic strategy that pairs diagnostic imaging with therapeutic isotopes to select and monitor patients. Programs focus on high unmet needs in oncology, leveraging collaborations with leading centers. Experienced teams manage development and regulatory paths while external partners provide specialized manufacturing. The goal is to expand options for patients with difficult to treat cancers through targeted, well characterized modalities.

Organization

Listed as: Brand page

Brand:

Ariceum Therapeutics

Country:

DE

Official page
  • Category: 7. Healthcare & Life Sciences
  • Subcategory: 7.6 Biotech
  • Technology: Radioligand therapy. Peptide targeting. Theranostics. GMP radioisotopes.
  • Release Date:
  • Canonical Url: